In the ever-evolving landscape of healthcare, it's vital for organizations to take steps toward bridging the gap between their clinical and marketing teams.
In the rapidly evolving landscape of healthcare, where scientific expertise intersects with market-driven strategies, it's vital for organizations to bridge the gap between their clinical and marketing factions.
A transformation is unfolding in some forward-thinking pharmaceutical entities, marked by the advent of leaders with diverse backgrounds and the introduction of interdisciplinary teams. These conglomerates are pushing the boundaries, integrating expertise from realms like marketing, insights, R&D, regulatory, clinical, and manufacturing. Such integrative approaches hint at the vast potential for innovation when there's a seamless blend of scientific rigor and market aspirations, aiming to revolutionize patient, caregiver, and healthcare professional (HCP) experiences globally.
As the world continues to grapple with increasingly complex healthcare challenges, the demand for holistic solutions has never been greater. Now more than ever, an integrated approach in healthcare—one that fuses the expertise of different departments—is of paramount importance.
This balance entails propelling product innovation to aptly confront market dynamics while curating messages that strike a chord with patients, caregivers, and HCPs. The core of this is rooted in robust scientific credibility. The magic comes from bringing the business disciplines together sooner in the product life cycle.
KS&R's recent customer feedback sessions unveiled a sentiment shared by a pharmaceutical executive in the oncology space:
“I think for the clinical opportunities that haven’t been commercialized yet, that’s a place where I see there is a lack of [market] insight. Even though it’s an important area for the future of the company, and we need to do important work to maximize that opportunity, the investment in insights doesn’t come as soon as I think it should, ideally.”
While both insights and clinical teams pivot on data gathering, study designs, and interpretation of findings, they often work in isolated bubbles. Bridging these separate worlds can amplify their collective strength and influence within an organization.
Presently, most manufacturers adhere to a segmented model. Yet, progressive entities are gravitating toward integration, aiming to achieve a harmonious blend where both teams amplify their collective contributions.
Why this emphasis on integration? The answer lies in the unique strengths and perspectives that different teams bring to the table:
With their depth of knowledge in medical science, patient care, and regulatory frameworks, clinical teams provide the bedrock of any healthcare solution. They ensure that products and services are both safe and effective for the end-users.
They understand the market, the competition, the latest trends, and most importantly, the needs and preferences of patients, caregivers, and HCPs. They can craft messages and strategies that resonate with the target audience, ensuring that innovations find their rightful place in the market.
Regardless of your role—be it in marketing, insights, or clinical—fostering collaboration is imperative:
It's pivotal to remember that the aim isn't to add complexity to the drug approval journey. Instead, the emphasis is on magnifying the value of clinical and market research collaboration.
However, it's not always smooth sailing. The convergence of these two distinct worlds poses its own set of challenges:
Given the stakes, deeper integration between clinical and insights teams is not just beneficial but essential. One of the most effective ways to facilitate this is through regular joint workshops. These sessions, where both teams come together to share their latest findings, discuss challenges, and set goals, can be instrumental in fostering mutual respect and understanding. In addition, cross-training programs can be invaluable. By providing opportunities for team members to familiarize themselves with the basics of the other's domain, we can bridge knowledge gaps.
For example, new marketers could greatly benefit from a course on clinical trials and the varying regulatory hurdles globally, while a clinical researcher might gain valuable insights from a workshop on unmet patient needs or brand building. Above all, setting shared objectives can play a pivotal role in this integration. Instead of each team working toward isolated departmental goals, establishing a unified objective that harnesses the expertise of both groups can truly revolutionize the way they collaborate and innovate.
When clinical and insights converge, where does the rubber meet the road? Three practical examples begin to demonstrate the value:
Such experiences validate the power of the combined forces of insights and clinical teams. In these specific cases:
When insights and clinical teams harmoniously align, the outcome is transformative. It's this synergy that underscores our commitment to bettering patient lives daily.
The future of healthcare undoubtedly lies in its ability to adapt, innovate, and integrate. By breaking down silos and fostering a culture of collaboration, we're not just bettering products and services, but truly living up to the promise of delivering the best possible care to patients.
Christine Nelson, VP and Principal at KS&R
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
In Focus: Addressing the Health Literacy Roadblock in Patient Recruitment
Published: November 15th 2024 | Updated: November 15th 2024With universal adoption of health literacy best practices slow going over the years, advocates are redefining the term to encompass much more of what health-related communication requires beyond simply words.